Tonix Announces First Patient Enrolled in Phase 2 MDD Study

Tonix enrolled the first patient in its Phase 2 HORIZON trial testing TNX-102 SL for major depressive disorder. This potential expansion into MDD builds upon the drug's previous success in fibromyalgia and could open a new market if results are positive.